Introduction: Hospitals increasingly make decisions regarding the early development of and investment in technologies, but a formal evaluation model for assisting hospitals early on in assessing the potential of innovative medical technologies is lacking. This article provides an overview of models for early assessment in different health organisations and discusses which models hold most promise for hospital decision makers.
Methods: A scoping review of published studies between 1996 and 2015 was performed using nine databases. The following information was collected: decision context, decision problem, and a description of the early assessment model.
Results: 2362 articles were identified and 12 studies fulfilled the inclusion criteria. An additional 12 studies were identified and included in the review by searching reference lists. The majority of the 24 early assessment studies were variants of traditional cost-effectiveness analysis. Around one fourth of the studies presented an evaluation model with a broader focus than cost-effectiveness. Uncertainty was mostly handled by simple sensitivity or scenario analysis.
Discussion And Conclusions: This review shows that evaluation models using known methods assessing cost-effectiveness are most prevalent in early assessment, but seems ill-suited for early assessment in hospitals. Four models provided some usable elements for the development of a hospital-based model.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.healthpol.2017.06.006 | DOI Listing |
Viruses
December 2024
Pharmalex India Pvt. Ltd., Noida 201301, India.
Nasal spray treatments that inhibit the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) entry into nose and nasopharynx at early stages can be an appropriate approach to stop or delay the progression of the disease. We performed a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicentric, phase II clinical trial comparing the rate of hospitalization due to COVID-19 infection between azelastine 0.1% nasal spray and placebo nasal spray treatment groups.
View Article and Find Full Text PDFViruses
November 2024
Institute for Parasitology, University of Veterinary Medicine Hannover, 30559 Hannover, Germany.
(OBVs) represent a diverse group of RNA viruses, encompassing a progressively increasing number of arboviruses that cause disease in both humans and livestock. Yet, studies investigating these viruses remain scarce despite the critical importance of such knowledge for assessing their zoonotic potential. In this study, we conducted an evaluation of the early immune response against the understudied Batai virus (BATV), as well as the influence of reassortment with the Bunyamwera virus (BUNV) on this response.
View Article and Find Full Text PDFViruses
November 2024
CSIRO, Australian Centre for Disease Preparedness (ACDP), Geelong, VIC 3220, Australia.
One of the key surveillance strategies for the early detection of an African swine fever (ASF) incursion into a country is the sampling of wild or feral pig populations. In Australia, the remote northern regions are considered a risk pathway for ASF incursion due to the combination of high numbers of feral pigs and their close proximity to countries where ASF is present. These regions primarily consist of isolated arid rangelands with high average environmental temperatures.
View Article and Find Full Text PDFViruses
November 2024
The Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Animal Health Laboratory, Australian Centre for Disease Preparedness, 5 Portarlington Road, East Geelong, VIC 3219, Australia.
A newly formatted enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to bluetongue virus (BTV) was developed and validated for bovine and ovine sera and plasma. Validation of the new sandwich ELISA (sELISA) was achieved with 949 negative bovine and ovine sera from BTV endemic and non-endemic areas of Australia and 752 BTV positive (field and experimental) sera verified by VNT and/or PCR. The test diagnostic sensitivity (DSe) and diagnostic specificity (DSp) were 99.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
Global Immunization Division, United States Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Background/objectives: Congenital rubella syndrome (CRS) is a constellation of serious multi-organ birth defects following rubella virus infection during early pregnancy. Countries in which rubella vaccination has not yet been introduced can have a high burden of this disease. Data on CRS burden and epidemiology are needed to guide the introduction of a rubella vaccine and monitor progress for rubella elimination, but the multi-system nature of CRS manifestations and required specialized testing creates a challenge for conducting CRS surveillance in developing settings such as Sudan.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!